Tirzepatide vs Semaglutide for Type 2 Diabetes
Released · Last reviewed
For type 2 diabetes, the SURPASS trials showed tirzepatide produced greater A1c reduction and weight loss than semaglutide in head-to-head and cross-trial comparisons. Both are effective; tirzepatide's dual mechanism tends to produce larger effects.
- SURPASS-2 compared tirzepatide directly against semaglutide in type 2 diabetes.
- Tirzepatide produced greater A1c reduction and weight loss.
- Both are effective diabetes drugs (Mounjaro, Ozempic).
- Choice depends on individual factors, tolerability, and coverage.
The diabetes context
Both semaglutide and tirzepatide are approved for type 2 diabetes — as Ozempic and Mounjaro respectively — and both lower blood glucose while producing weight loss. For diabetes, the primary outcome is glycemic control, measured by A1c, with weight loss as an important secondary benefit.
The question of which is more effective for diabetes has unusually strong evidence, because they were compared directly.
This head-to-head data is rarer than cross-trial comparison and therefore more reliable.
The SURPASS-2 head-to-head
SURPASS-2 directly compared tirzepatide against semaglutide in people with type 2 diabetes. Tirzepatide produced greater reductions in A1c and greater weight loss than semaglutide across the doses studied.
This makes tirzepatide the more potent option for glycemic control and weight loss in the studied population, consistent with its dual GIP/GLP-1 mechanism versus semaglutide's single GLP-1 action.
The magnitude of difference grew at higher tirzepatide doses, though both drugs were effective.
| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 | GLP-1 only |
| Brand (diabetes) | Mounjaro | Ozempic |
| A1c reduction | Greater (SURPASS-2) | Strong |
| CV outcome data | Emerging | Extensive (SUSTAIN) |
How clinicians choose
Greater potency does not automatically make tirzepatide the right choice for everyone. Clinicians weigh individual factors: tolerability, other medical conditions, cardiovascular risk profile (where semaglutide has extensive outcome data), cost, and insurance coverage.
For a patient who tolerates it and needs maximum glycemic and weight effect, tirzepatide's potency is attractive. For a patient prioritizing established cardiovascular outcome evidence, semaglutide's larger CVOT base matters.
The decision is individualized, not a simple ranking.
Coverage and cost
For diabetes, both drugs are typically covered by insurance including Medicare, unlike the weight-loss indications. This makes the brand products more accessible for diabetes than for weight management.
Cost and formulary placement can influence the choice: a plan may prefer one over the other, and copays differ. The clinical difference in potency is real, but access often shapes the practical decision.
The diabetes brands (Mounjaro, Ozempic) are the labeled products; compounded versions are a separate, non-approved category.
| Priority | Favors |
|---|---|
| Maximum A1c/weight effect | Tirzepatide |
| Established CV outcomes | Semaglutide |
| Coverage/cost | Depends on plan |
The bottom line
For type 2 diabetes, SURPASS-2 showed tirzepatide produces greater A1c reduction and weight loss than semaglutide head-to-head, reflecting its dual mechanism. Both are effective.
The choice depends on tolerability, cardiovascular evidence needs, cost, and coverage — not potency alone. Both are typically covered for diabetes, including by Medicare.
This is educational information; the choice between them is a clinical decision.
Frequently asked questions
Is tirzepatide better than semaglutide for diabetes?
In SURPASS-2, tirzepatide produced greater A1c reduction and weight loss head-to-head. Both are effective; the best choice depends on individual factors.
Are both covered for diabetes?
Both are typically covered by insurance including Medicare for type 2 diabetes, unlike their weight-loss indications.
Why is tirzepatide more potent?
Its dual GIP/GLP-1 mechanism tends to produce larger glycemic and weight effects than semaglutide's single GLP-1 action.
Should everyone with diabetes choose tirzepatide?
No. Semaglutide has more extensive cardiovascular outcome data, and factors like tolerability, cost, and coverage matter. The choice is individualized.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- NEJM — STEP, SELECT, SURMOUNT, SURPASS, SUSTAIN, FLOW trial publications.
- ClinicalTrials.gov and prescribing information.
- Evidence policy: evidence policy.
The numbers behind this page
The tirzepatide price range, stated precisely
Standard-dose compounded tirzepatide runs $86 to $299 a month across the 24 programmes we priced on October 15, 2026, with a median of $144. The spread is $213 a month, or $2,556 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $126 and Eden at $129; lower stickers come with a sale, a prepaid term or a membership. Half the programmes sit below $144 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Four programmes printed a tirzepatide microdose price on October 15, 2026, from $116 (Telos RX, "as low as") to $199 (Shed). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
What we do not claim in tirzepatide
On October 15, 2026, compounded tirzepatide ran $86 to $299 a month across the 24 programmes we priced.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
Standard-dose tirzepatide spans $86 to $299 a month across the 24 programmes we priced on October 15, 2026, a spread of $213.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We show month-to-month and prepaid figures side by side for that reason. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Does compounded tirzepatide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed tirzepatide cheaper?
Because it is less medicine. On October 15, 2026, four programs printed a tirzepatide microdose price, from $116 (Telos RX, "as low as") to $199 (Shed); NexLife's microdose plan was $189 month-to-month or $147 a month on 12 months; since November 8, 2026 it is $129 or $115, the same as the standard plan. A microdose sits below every dose studied in the pivotal trials.
What does compounded tirzepatide cost per month in October 2026?
As of October 15, 2026, the 24 compounded tirzepatide programs we could price on their own pages charge between $86 and $299 a month at their lowest all-in rate, with a median of $144, counting any required membership and the cheapest plan term each program prints. The $86 figure is Collective's $69 monthly price plus its $199 annual membership spread over twelve months. Standing month-to-month rates with no membership start at $126 (Mondae) and $129 (Eden); as of November 6, 2026, NexLife is $129 month-to-month and $115 on a 12-month plan. Compounded tirzepatide is not FDA-approved.
What does compounded tirzepatide normally cost?
$86 to $299 a month at the lowest all-in rate across the 24 programs we priced on October 15, 2026, with a median of $144. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.